These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34071587)

  • 21. Ten-Year Outcomes of Moderately Hypofractionated Salvage Postprostatectomy Radiation Therapy and External Validation of a Contemporary Multivariable Nomogram for Biochemical Failure.
    Chin S; Fatimilehin A; Walshaw R; Argarwal A; Mistry H; Elliott T; Logue J; Wylie J; Choudhury A
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):288-296. PubMed ID: 31987961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
    Ramey SJ; Agrawal S; Abramowitz MC; Moghanaki D; Pisansky TM; Efstathiou JA; Michalski JM; Spratt DE; Hearn JWD; Koontz BF; Liauw SL; Pollack A; Anscher MS; Den RB; Stephans KL; Zietman AL; Lee WR; Stephenson AJ; Tendulkar RD
    Eur Urol; 2018 Jul; 74(1):99-106. PubMed ID: 29128208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.
    Song C; Byun SJ; Kim YS; Ahn H; Byun SS; Kim CS; Lee SE; Kim JS
    PLoS One; 2019; 14(4):e0215057. PubMed ID: 30973905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
    Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
    World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer.
    Lee SU; Kim JS; Kim YS; Cho J; Choi SH; Nam TK; Jeong SM; Kim Y; Choi Y; Lee DE; Park W; Cho KH
    Cancer Res Treat; 2022 Oct; 54(4):1191-1199. PubMed ID: 34883554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lead-time bias does not falsify the efficacy of early salvage radiotherapy for recurrent prostate cancer.
    Bartkowiak D; Thamm R; Siegmann A; Böhmer D; Budach V; Wiegel T
    Radiother Oncol; 2021 Jan; 154():255-259. PubMed ID: 32920006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PSA-response to salvage radiotherapy after radical prostatectomy correlates with freedom from progression and overall survival.
    Bartkowiak D; Bottke D; Thamm R; Siegmann A; Hinkelbein W; Wiegel T
    Radiother Oncol; 2016 Jan; 118(1):131-5. PubMed ID: 26653358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
    Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
    Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
    Tendulkar RD; Agrawal S; Gao T; Efstathiou JA; Pisansky TM; Michalski JM; Koontz BF; Hamstra DA; Feng FY; Liauw SL; Abramowitz MC; Pollack A; Anscher MS; Moghanaki D; Den RB; Stephans KL; Zietman AL; Lee WR; Kattan MW; Stephenson AJ
    J Clin Oncol; 2016 Oct; 34(30):3648-3654. PubMed ID: 27528718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twelve-year outcomes of prostate cancer after radical prostatectomy for T3 and/or positive margins managed with surveillance or salvage radiation therapy, based on risk groups.
    Goy BW; Amy Liu IL
    Prostate Int; 2021 Dec; 9(4):190-196. PubMed ID: 35059356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salvage Radiation Therapy for Biochemical Failure Following Radical Prostatectomy.
    Spieler B; Goldstein J; Lawrence YR; Saad A; Berger R; Ramon J; Dotan Z; Laufer M; Weiss I; Tzvang L; Poortmans P; Symon Z
    Isr Med Assoc J; 2017 Jan; 19(1):19-24. PubMed ID: 28457109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macroscopic locoregional relapse from prostate cancer: which role for salvage radiotherapy?
    Bruni A; Ingrosso G; Trippa F; Di Staso M; Lanfranchi B; Rubino L; Parente S; Frassinelli L; Maranzano E; Santoni R; Sighinolfi MC; Lohr F; Mazzeo E
    Clin Transl Oncol; 2019 Nov; 21(11):1532-1537. PubMed ID: 30868389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value, sensitivity, and specificity of multiparametric magnetic resonance imaging before salvage radiotherapy for prostate cancer.
    Breen WG; Stish BJ; Harmsen WS; Froemming AT; Mynderse LA; Choo CR; Davis BJ; Pisansky TM
    Radiother Oncol; 2021 Aug; 161():9-15. PubMed ID: 34023327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
    Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival.
    Casas F; Valduvieco I; Oses G; Izquierdo L; Archila I; Costa M; Cortes KS; Barreto T; Ferrer F
    Clin Transl Oncol; 2019 Mar; 21(3):355-362. PubMed ID: 30128953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.
    Tumati V; Jackson WC; Abugharib AE; Raj G; Roehrborn C; Lotan Y; Courtney K; Bagrodia A; Gahan JC; Zumsteg ZS; Folkert MR; Laine AM; Hannan R; Spratt DE; Desai NB
    BJU Int; 2018 Mar; 121(3):365-372. PubMed ID: 28581200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer.
    Bartkowiak D; Siegmann A; Böhmer D; Budach V; Wiegel T
    BJU Int; 2019 Nov; 124(5):785-791. PubMed ID: 31220400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized prospective phase III trial of
    Calais J; Czernin J; Fendler WP; Elashoff D; Nickols NG
    BMC Cancer; 2019 Jan; 19(1):18. PubMed ID: 30616601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
    BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.